A major concern in prostate brachytherapy is rectal toxicity, which mainly depends on the dose and volume of rectum involved by radiation. We hypothesize that the rectal distension, as produced by constipation, influences the dosimetric parameters of the rectum and other pelvic organs.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
An open, controlled, prospective, paired trial (pre-post test) was designed and conducted. Twenty-three patients treated with prostate brachytherapy were recruited, of which 21 were evaluated. All of them underwent two CT scans, the first one with empty rectum and the second with rectum distended by a catheter balloon. Target volumes and organs at risk were delineated, and dosimetric parameters were calculated and then compared for each patient between both CT.
For rectum, D2cc increased 15. 8% (p < 0. 001) and D0. 1cc 24. 05% (p = 0. 002) when the rectum was full. A significant difference was also found in dose distribution to prostate, when rectum is distended, a 1% decrease in V100 (p = 0. 031) and a 3. 25% in D90 (p = 0. 033) was registered.
The status of rectal distension, as occurs in constipation, has a deleterious influence on prostate brachytherapy dosimetry. This situation increases the radiation to rectum and modifies dose distribution to prostate. We recommend prevention of constipation for at least two half lives of the radioactive seeds.
Journal of contemporary brachytherapy. 2015 Aug 18 [Epub]
L Fernando Otón, M Carmen Dolado, Eduardo J Núñez, Claudio A Otón
Radiation Oncology Department, Hospital Universitario de Canarias ; Department of Physical Medicine and Pharmacology, La Laguna University. , Radiation Oncology Department, Hospital Universitario de Canarias. , Medical Physics Department, Hospital Universitario de Canarias, Canary Islands, Spain. , Radiation Oncology Department, Hospital Universitario de Canarias ; Department of Physical Medicine and Pharmacology, La Laguna University.